Cargando…
Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes
Autores principales: | DiNicolantonio, James J, H O'Keefe, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896029/ https://www.ncbi.nlm.nih.gov/pubmed/35236761 http://dx.doi.org/10.1136/openhrt-2022-001989 |
Ejemplares similares
-
Low-grade metabolic acidosis as a driver of insulin resistance
por: DiNicolantonio, James J, et al.
Publicado: (2021) -
The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol
por: Guarnieri, Gabriella, et al.
Publicado: (2023) -
Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome
por: Kamenov, Zdravko, et al.
Publicado: (2023) -
Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
por: Merviel, Philippe, et al.
Publicado: (2021) -
Low-grade metabolic acidosis as a driver of chronic disease: a 21st century public health crisis
por: DiNicolantonio, James J, et al.
Publicado: (2021)